Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia

Autor:	Traci Kruer, Naseema Gangat, Darci Zblewski, Moritz Binder, Ayalew Tefferi, Rami S. Komrokji, Aref Al-Kali, Hannah Newman, Mrinal M. Patnaik, Cameron Durrant, Abhishek A. Mangaonkar, David A. Sallman, Christopher Letson, Eric Padron, Alan F. List, Maria E. Balasis, Ted Shih, Rachel Heuer, Jeffery Hirvela, Adrian Lo
Rok vydání:	2020
Předmět:	0301 basic medicine Male Drug-Related Side Effects and Adverse Reactions Maximum Tolerated Dose medicine.medical_treatment Immunology Chronic myelomonocytic leukemia Antibodies Monoclonal Humanized Biochemistry law.invention 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological law hemic and lymphatic diseases medicine Humans Letter to Blood Aged Aged 80 and over Chemotherapy biology Dose-Response Relationship Drug business.industry Antibodies Monoclonal Granulocyte-Macrophage Colony-Stimulating Factor Leukemia Myelomonocytic Chronic Cell Biology Hematology Middle Aged medicine.disease Recombinant Proteins Leukemia 030104 developmental biology Granulocyte macrophage colony-stimulating factor LENZILUMAB Treatment Outcome Chemotherapy Adjuvant 030220 oncology & carcinogenesis Monoclonal biology.protein Recombinant DNA Female Antibody business medicine.drug
Zdroj:	Blood
ISSN:	1528-0020
Popis:	In this phase 1 trial, inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF) was associated with clinically meaningful responses in 5 of 15 patients with relapsed or refractory chronic myelomonocytic leukemia (CMML). Preliminary data suggest that this approach may be tractable in CMML bearing activating NRAS mutations.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40ac9dae8cdc999bbf122a368a3a4e8d https://pubmed.ncbi.nlm.nih.gov/32294158 Zobrazit plný text záznamu